We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
SBRT for early-stage glottic larynx cancer—Initial clinical outcomes from a phase I clinical trial.
- Authors
Schwartz, David L.; Sosa, Alan; Chun, Stephen G.; Ding, Chiuxiong; Xie, Xian-Jin; Nedzi, Lucien A.; Timmerman, Robert D.; Sumer, Baran D.
- Abstract
Purpose: To confirm safety and feasibility of hypofractionated SBRT for early-stage glottic laryngeal cancer. Methods: Twenty consecutive patients with cTis-T2N0M0 carcinoma of glottic larynx were enrolled. Patients entered dose-fractionation cohorts of incrementally shorter bio-equivalent schedules starting with 50 Gy in 15 fractions (fx), followed by 45 Gy/10 fx and, finally, 42.5 Gy/5 fx. Maximum combined CTV-PTV expansion was limited to 5 mm. Patients were treated on a Model G5 Cyberknife (Accuray, Sunnyvale, CA). Results: Median follow-up is 13.4 months (range: 5.6–24.6 months), with 12 patients followed for at least one year. Maximum acute toxicity consisted of grade 2 hoarseness and dysphagia. Maximum chronic toxicity was seen in one patient treated with 45 Gy/10 fx who continued to smoke >1 pack/day and ultimately required protective tracheostomy. At 1-year follow-up, estimated local disease free survival for the full cohort was 82%. Overall survival is 100% at last follow-up. Conclusions: We were able to reduce equipotent total fractions of SBRT from 15 to 5 without exceeding protocol-defined acute/subacute toxicity limits. With limited follow-up, disease control appears comparable to standard treatment. We continue to enroll to the 42.5 Gy/5 fx cohort and follow patients for late toxicity. Trial registration: ClinicalTrials.gov
- Subjects
LARYNGEAL cancer; CLINICAL trials; TRACHEOTOMY; PREVENTIVE medicine; COHORT analysis
- Publication
PLoS ONE, 2017, Vol 12, Issue 3, p1
- ISSN
1932-6203
- Publication type
Article
- DOI
10.1371/journal.pone.0172055